glucagon receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示,参与者在体重和相关代谢指标上出现变化,但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置,以区分药物效应与行为干预。监管提交和标签范围尚未确定;长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比,瑞他鲁肽增加胰高血糖素受体成分,理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制,目前尚无定论。胃肠道反应是该类药物常见不良事件,试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽;LY3437943 | 名称拼写可能因语言和出版物而异 |
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
=== Validity === SPINA-GBeta significantly correlates with the M value in glucose clamp studies and (better than HOMA-Beta) with the two-hour value in oral glucose tolerance testing (OGTT), glucose rise in OGTT, subscapular skinfold, truncal fat content and the HbA1c fraction. It has the additional advantage that it circumvents the HOMA-blind zone, which renders the calculation of HOMA-Beta impossible if the fasting glucose concentration is 3.5 mmol/L (63 mg/dL) or below. Unlike HOMA-Beta, SPINA-Beta can be sensibly calculated in the whole range of measurements.
A new Hardee's logo was unveiled in 2006 that featured script lettering and retained the iconic Happy Star, further unifying the Hardee's and Carl's Jr. brands. Hardee's also marketed special Super Bowl celebratory pins in the early 1990s.
Furthermore, the three subunits, α, β, and γ have additional four main classes based on their primary sequence. These include Gs, Gi, Gq and G12. Type 3: Kinase-linked and related receptors (see "Receptor tyrosine kinase" and "Enzyme-linked receptor") – They are composed of an extracellular domain containing the ligand binding site and an intracellular domain, often with enzymatic-function, linked by a single transmembrane alpha helix. The insulin receptor is an example. Type 4: Nuclear receptors – While they are called nuclear receptors, many are actually located in the cytoplasm and migrate to the nucleus after binding with their ligands. They are composed of a C-terminal ligand-binding region, a core DNA-binding domain (DBD) and an N-terminal domain that contains the AF1(activation function 1) region. The core region has two zinc fingers that are responsible for recognizing the DNA sequences specific to this receptor. The N terminus interacts with other cellular transcription factors in a ligand-independent manner; and, depending on these interactions, it can modify the binding/activity of the receptor. Steroid and thyroid-hormone receptors are examples of such receptors. Membrane receptors may be isolated from cell membranes by complex extraction procedures using solvents, detergents, and/or affinity purification. The structures and actions of receptors may be studied by using biophysical methods such as X-ray crystallography, NMR, circular dichroism, and dual polarisation interferometry.
The European Bioinformatics Institute (EMBL-EBI) is an intergovernmental organization (IGO) which, as part of the European Molecular Biology Laboratory (EMBL) family, focuses on research and services in bioinformatics. It is located on the Wellcome Genome Campus in Hinxton near Cambridge, and employs over 600 full-time equivalent (FTE) staff. Further, the EMBL-EBI hosts training programs that teach scientists the fundamentals of the work with biological data and promote the plethora of bioinformatic tools available for their research, both EMBL-EBI-based and not so. One of the roles of the EMBL-EBI is to index and maintain biological data in a set of databases, including Ensembl (housing whole genome sequence data), UniProt (protein sequence and annotation database) and Protein Data Bank (protein and nucleic acid tertiary structure database). A variety of online services and tools is provided, such as Basic Local Alignment Search Tool (BLAST) or Clustal Omega sequence alignment tool, enabling further data analysis.
These employ the same radioligands and have the same uses as SPECT scanning, but are able to provide even finer 3-D localization of high-uptake tissues, in cases where finer resolution is needed. An example is the sestamibi parathyroid scan which is performed using the 99mTc radioligand sestamibi, and can be done in either SPECT or SPECT/CT machines.
Sources: en.wikipedia.org
== External links == "Glucagon Receptor Family: GLP-1". The International Union of Basic and Clinical Pharmacology, The British Pharmacological Society, The University of Edinburgh. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2007-10-25. glucagon-like+peptide+receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P43220 (Glucagon-like peptide 1 receptor) at the PDBe-KB.
She saw the base of the Battalion "Vostok" in Gudermes somewhere in that time frame. Chechen soldiers were preparing to go to South Ossetia. It was claimed that they were going to support the peacekeeping mission. At 3:30 am they began preparing for departure with military official reminding them not to forget their passports and military IDs. However, the article does not mention that there was any war in South Ossetia. On 10 August 2008, Moskovskij Komsomolets published a report by journalist who was in Tskhinvali on the night of 7 August. The report states, "There are 1700 peacekeepers here." According to Russian Defence Ministry official, the 1990s ceasefire agreement allowed Russia to station 500 peacekeepers in the conflict zone with 300 additional peacekeepers being reserved to be deployed during emergency. On 10 August 2008, Izvestia published a report by journalist who had been in Tskhinvali. Journalist Yuri Snegirev wrote that he had witnessed Russian military servicemen, who were not peacekeepers, in Tskhinvali bomb shelter on 8 August 2008. On 12 August 2008, Komsomolskaya Pravda reported that in South Ossetia, several soldiers were wounded and one was killed, who were from Tatarstan. Five days before he was killed in South Ossetia, Evgeny Parfenov warned his parents not to call him because it would be hard to reach him by phone. Lieutenant Aleksandr Popov was participating in the exercises on the height near Tskhinvali when his group was requested by the intelligence to reinforce them.
Established in 1889, the University of Cincinnati College of Nursing was the first school to offer a baccalaureate degree in nursing in 1916. In 1942, the college became a charter member of the National League for Nursing. In 2002 the college was the first nursing school to offer cooperative education in addition to clinical time, and in 2010 it began a Doctorate of Nursing Practice. Successes include awarding over $1.0 million in scholarships and graduate assistantship stipends for the 2008 – 2009 academic year, ranking in the top 10 percent of American nursing programs, receiving over $2.6 million in extramural research awards during the 2009 fiscal year and developing partnerships with over 300 clinical sites. In 1982, the college was one of eleven nursing schools that received the Robert Wood Johnson Teaching Nursing Home Project Grant. In 1987, IBM chose the college as one of fifteen to develop computer-assisted interactive video for health sciences. A nursing doctoral program and nurse anesthetist master's program were established in 1990. In 1992, the college established a joint master's degree (MSN/MBA) with the Lindner College of Business.
Nucleic acids, so-called because of their prevalence in cellular nuclei, is the generic name of this family of biopolymers. They are complex, high-molecular-weight biochemical macromolecules that encode genetic information in all living cells and viruses. Their monomers are called nucleotides, and each consists of three components: a nitrogenous heterocyclic base (either a purine or a pyrimidine), a pentose sugar, and a phosphate group.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段,任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体,而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应,但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.